Double adjuvanting strategy for peptide-based vaccines: trimethyl chitosan nanoparticles for lipopeptide delivery.
OBJECTIVE
To develop novel polymer-based nanoscale delivery system for lipopeptide-based vaccine against group A Streptococcus (GAS).


METHODS
Four types of lipopeptide antigen-loaded polymeric nanoparticles (NP) were prepared. NP were accessed for their capacity to be taken up by dendritic cells; effect on dendritic cell maturation; ability to induce mucosal and systemic immunity; and capability to induce antibody responses that opsonize GAS bacteria.


CONCLUSIONS
The combination of adjuvanting properties of lipopeptides and dextran/trimethyl chitosan-based NP had a synergistic effect on humoral immunity, and the produced antibodies showed high opsonic activity against clinical GAS isolates.


CONCLUSIONS
Biocompatible NP-bearing trimethyl chitosan and dextran are efficient as mucosal adjuvants for the intranasal delivery of lipopeptide-based vaccines.
School of Chemistry & Molecular Biosciences, The University of Queensland, St Lucia, QLD 4072, Australia.
Nirmal
N
Marasini
School of Chemistry & Molecular Biosciences, The University of Queensland, St Lucia, QLD 4072, Australia.
Ashwini K
AK
Giddam
Institute for Molecular Biosciences, The University of Queensland, St Lucia, QLD 4072, Australia.|Diamantina Institute, The University of Queensland, Woolloongabba, QLD, 4102, Australia.
Zeinab G
ZG
Khalil
School of Chemistry & Molecular Biosciences, The University of Queensland, St Lucia, QLD 4072, Australia.
Waleed M
WM
Hussein
Institute for Molecular Biosciences, The University of Queensland, St Lucia, QLD 4072, Australia.
Robert J
RJ
Capon
Institute for Glycomics, Griffith University, Gold Coast, QLD 4222, Australia.
Michael R
MR
Batzloff
Institute for Glycomics, Griffith University, Gold Coast, QLD 4222, Australia.
Michael F
MF
Good
School of Chemistry & Molecular Biosciences, The University of Queensland, St Lucia, QLD 4072, Australia.|Institute for Molecular Biosciences, The University of Queensland, St Lucia, QLD 4072, Australia.|School of Pharmacy, The University of Queensland, Woolloongabba, QLD 4102, Australia.
Istvan
I
Toth
School of Chemistry & Molecular Biosciences, The University of Queensland, St Lucia, QLD 4072, Australia.
Mariusz
M
Skwarczynski
D000276:Adjuvants, Immunologic; D000281:Administration, Intranasal; D000818:Animals; D002478:Cells, Cultured; D048271:Chitosan / Q000737:chemistry*; D003713:Dendritic Cells / Q000166:cytology / Q000187:drug effects / Q000276:immunology; D003911:Dextrans / Q000737:chemistry; D016503:Drug Delivery Systems; D005260:Female; D055666:Lipopeptides / Q000008:administration & dosage* / Q000737:chemistry / Q000276:immunology; D051379:Mice; D053758:Nanoparticles / Q000008:administration & dosage* / Q000737:chemistry; D013290:Streptococcal Infections / Q000276:immunology / Q000517:prevention & control; D022541:Streptococcal Vaccines / Q000008:administration & dosage* / Q000276:immunology; D013297:Streptococcus pyogenes / Q000187:drug effects* / Q000276:immunology
D000276:Adjuvants, Immunologic; D003911:Dextrans; D055666:Lipopeptides; D022541:Streptococcal Vaccines; D048271:Chitosan
Group A Streptococcus; chitosan; dextran; lipopeptides; nasal; vaccine